Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Itraconazole on TAK-954 PK in Healthy Adults
NCT03173170Phase 1Completed
- Sponsor
- Takeda
- Start
- May 2017
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of felcisetrag in gastroparesis and enteral feeding intolerance (EFI), sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Plasma Concentration-time Curve From Time 0 to Infinity. Started May 2017; status: completed.
02
Drugs
felcisetrag
03
Conditions
gastroparesisenteral feeding intolerance (EFI)
Beyond the preview
Go deeper on NCT03173170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03173170.